Reducing blood pressure in people of different ages

BMJ

Volumn 336, Issue 7653, 2008, Pages 1080-1081

  Staessen, Jan A ^a   Richart, Tom ^b   Verdecchia, Paolo ^c  

^a Studies Coordinating Centre   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; PLACEBO;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; EDITORIAL; FOLLOW UP; GROUPS BY AGE; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 44349099306     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39560.541725.80     Document Type: Editorial

References (12)

1. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; doi: 10.1136/bmj.39548.738368.BE.
2. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
3. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis (erratum published in Lancet 2002;359:360). Lancet 2001;358:1305-15.
4. Verdecchia P, Reboldi G, Angeli A, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-Converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46:386-92.
5. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
6. Staessen JA, G sowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72.
7. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358 (epub ahead of print 31 March 2008).
8. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999;353:793-6.
9. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: joint British societies' guidelines on prevention of cardiovascular diseases in clinical practice. Heart 2006;91:1-52.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
11. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2007 guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462-536.
12. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.